Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia

Author:

Aggarwal Anupriya,Stella Alberto Ospina,Walker Gregory,Akerman Anouschka,Esneau Camille,Milogiannakis Vanessa,Burnett Deborah L.,McAllery Samantha,Silva Mariana RuizORCID,Lu Yonghui,Foster Charles S. P.,Brilot Fabienne,Pillay Aleha,Van Hal SabastiaanORCID,Mathivanan Vennila,Fichter Christina,Kindinger Andrea,Hoppe Alexandra Carey,Munier Mee LingORCID,Amatayakul-Chantler SupavadeeORCID,Roth Nathan,Coppola Germano,Symonds Geoff P.,Schofield Peter,Jackson Jennifer,Lenthall Helen,Henry Jake Y.,Mazigi Ohan,Jäck Hans-Martin,Davenport Miles P.,Darley David R.ORCID,Matthews Gail V.,Khoury David S.,Cromer Deborah,Goodnow Christopher C.,Christ Daniel,Robosa RoselleORCID,Starck Damien J.,Bartlett Nathan W.,Rawlinson William D.,Kelleher Anthony D.,Turville Stuart G.ORCID

Abstract

AbstractGenetically distinct variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged since the start of the COVID-19 pandemic. Over this period, we developed a rapid platform (R-20) for viral isolation and characterization using primary remnant diagnostic swabs. This, combined with quarantine testing and genomics surveillance, enabled the rapid isolation and characterization of all major SARS-CoV-2 variants circulating in Australia in 2021. Our platform facilitated viral variant isolation, rapid resolution of variant fitness using nasopharyngeal swabs and ranking of evasion of neutralizing antibodies. In late 2021, variant of concern Omicron (B1.1.529) emerged. Using our platform, we detected and characterized SARS-CoV-2 VOC Omicron. We show that Omicron effectively evades neutralization antibodies and has a different entry route that is TMPRSS2-independent. Our low-cost platform is available to all and can detect all variants of SARS-CoV-2 studied so far, with the main limitation being that our platform still requires appropriate biocontainment.

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Microbiology (medical),Genetics,Applied Microbiology and Biotechnology,Immunology,Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3